Survival data back Tagrisso's role in first-line lung cancer

Survival data back Tagrisso's role in first-line lung cancer

Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?

Osimertinib Combo Significantly Prolongs Survival in Advanced EGFR+ NSCLC

Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.

AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).The post AstraZeneca’s Tagrisso combo shows OS improvement in Phase III NSCLC trial appeared first on Clinical Trials Arena.

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy. The study demonstrated a statistically significant and…

Final FLAURA2 Results Confirm Survival Advantage of Tagrisso Plus Chemotherapy in Advanced EGFRm Lung Cancer

Open the article to view the coverage from EuropaWire.eu